Hyunsun Jo

CEO

Pin Therapeutics

Short Biography

Hyunsun Jo received his B.S and Ph.D. degrees in Biological Sciences from Seoul National University and performed post-doctoral research at Gladstone Institute at UCSF. He has spent the past 14 years as a biotech entrepreneur in the biotech industry, focusing on targeted protein degradation, where he has led new E3 ligase ligand discovery and conducted target validation across a wide range of proteins.

Presentation Topic: First-in-Human Phase 1a Study of PIN-5018, a CK1α-selective MGD, in Advanced Solid Tumors

• CK1α regulates key survival pathways and is dysregulated in solid tumors, supporting its therapeutic potential.

• PIN-5018 induces CK1α degradation with antitumor activity in preclinical models.

• Currently evaluating safety, PK/PD, and preliminary efficacy in advanced solid tumor patients.